​

August 2023

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • MORAb-202: [2+] to [3+] under Europe – Active Clinical Trials

  • BT5528 & BT8009: Studies for both are categorized under Phase 1 AND 2 per clinicaltrials.gov and company's website. Both compounds added to Phase 2 table.

​

June 2023:

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • RC-88: [2+] to [3+] under US – Active Clinical Trials​

• Plocabulin (PM184) was removed as there are currently no active trials.

​

April 2023:

•  All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly:

  • ​​Ladiratuzumab vedotin (SGN-LIV1A): [5+] to [4+] under US – Active Clinical Trials
  • Bryostatin: [1+] to None under US – Active Clinical Trials
  • MORAb-202: [2+] to [3+] under US – Active Clinical Trials; None to [2+] under Europe – Active Clinical Trials
  • MRG003: [5+] to [6+] under US – Active Clinical Trials
  • RC-88: [1+] to [2+] under US – Active Clinical Trials
  • STI-6129: [4+] to [5+] under US – Active Clinical Trials
  • ARX-788: None to [1+] under Europe – Active Clinical Trials
  • Upifitamab rilsodotin (XMT-1536): [2+] to [3+] under US – Active Clinical Trials; None to [1+] under Europe – Active Clinical Trials

 

February 2023:

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

• Compound name and molecular target has been updated for MORAb-202

• Link has been added for chemical class for XMT-1536
   

December 2022:

• All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.

• The number of current clinical trials was updated accordingly.

• Links have been added for chemical class for several compounds.

• Link has been added for compound name for MRG003

• 4 new compounds were added: RC-88, STI-6129, ARX-788, and Upifitamab rilsodotin (XMT-1536).

​

September 2022: 

• During September copyright notices were posted on the top and bottom of this page. Date of the last update has been edited. All the links have been checked and were working properly.

• GTS-21 was removed as currently there are no clinical trials and no institutional support for further development.  

• Telisotuzumab vedotin (ABBV-399) has 4 US clinical trials (https://clinicaltrials.gov/ct2/results?term=abbv399&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt ).

• CAB-ROR2 (BA-3021, Ozuriftamab Vedotin) has a new active European clinical trial (https://www.clinicaltrialsregister.eu/ctr-search/search?query=Ozuriftamab+Vedotin&status=ongoing).  

• BA-3011 (Mecbotamab Vedotin) has a new active European clinical trial (https://www.clinicaltrialsregister.eu/ctr-search/search?query=Mecbotamab+Vedotin&status=ongoing) and has been added to the Phase 2 page.

• MORAb-202 (Farletuzumab Ecteribulin) has a US Active Phase 2 trial (https://www.clinicaltrials.gov/ct2/show/NCT04300556?recrs=abdf&cond=MORAb-202&draw=2&rank=2) and has been moved to the Phase 2 webpage.

• MRG003 has 5 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/results?cond=mrg003&term=&cntry=&state=&city=&dist=&Search=Search) and has been moved to the Phase 2 webpage.

• A-166 has 2 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/show/NCT05346328?cond=A-166&draw=2&rank=3) and has been moved to the Phase 2 webpage. 

​

​